Company: TELO
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010298
Chunk: 62

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Item 1
Chunk 62
---
    in operating assets and liabilities: 

    Trade
    accounts payable and accrued expenses 
     (28,675) 
     74,744)

    Prepaid
    expenses 
     (30,315) 
     (98,095 

    Net cash
    flows from operating activities 
    $(863,132) 
    $(1,939,415)

    Financing
    activities: 

    Payments
    under related party line of credit 
     -  
     (101,000 

    Payments
    to related party 
     -  
     (519,475)

    Proceeds
    from sale of common stock 
     -  
     5,832,973 

    Net cash
    flows from financing activities 
     -  
     5,212,498 

    Net change in cash and cash equivalents 
     (863,132) 
     3,273,083 

    Cash and cash equivalents, beginning of
    period 
     1,266,131  
     1,231 

    Cash and cash equivalents, end of
    period 
    $402,999  
    $3,274,314 

    Supplemental disclosure of cash flow information 

    Cash paid for interest 
    $-  
    $- 

    Cash paid for income taxes 
    $-  
    $- 

See notes to condensed unaudited financial statements

6

TELOMIR
PHARMACEUTICALS, INC.

NOTES
TO CONDENSED FINANCIAL STATEMENTS

FOR
THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024

(Unaudited)

Note
1. Description of business and summary of significant accounting policies:

Overview

Telomir-1
is a novel oral small molecule metal ion regulator designed to extend telomere caps, maintain cellular balance, and combat oxidative
stress, a key driver of aging and disease progression. By modulating essential metal ions such as iron, and copper, Telomir-1 may help
protect against age related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s
disease (a genetic disorder leading to toxic copper buildup in the body), and Age-related Macular Degeneration (AMD), as well as Type
2 Diabetes, cancer, and